Respiratory Syncytial Virus Vaccines
"Respiratory Syncytial Virus Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
| Descriptor ID |
D022261
|
| MeSH Number(s) |
D20.215.894.899.730
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus Vaccines".
This graph shows the total number of publications written about "Respiratory Syncytial Virus Vaccines" by people in this website by year, and whether "Respiratory Syncytial Virus Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 7 | 0 | 7 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus Vaccines" by people in Profiles.
-
Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children. JAMA Pediatr. 2026 Mar 01; 180(3):314-324.
-
Comparison of immunization information systems, electronic medical records, and self-report to ascertain RSV vaccination status among US adults aged =60?years, 2023-2024. Vaccine. 2026 Jan 01; 69:127946.
-
The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation. Lancet Glob Health. 2025 Dec; 13(12):e2165-e2174.
-
RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28; 334(16):1442-1451.
-
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 May 08; 74(16):273-281.
-
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
-
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination. JAMA Netw Open. 2025 04 01; 8(4):e252841.
-
New Approaches to Respiratory Syncytial Virus Prevention and Treatment. Annu Rev Med. 2025 01; 76(1):13-28.
-
Seasonality, Clinical Characteristics, and Outcomes of Respiratory Syncytial Virus Disease by Subtype Among Children Aged <5 Years: New Vaccine Surveillance Network, United States, 2016-2020. Clin Infect Dis. 2024 05 15; 78(5):1352-1359.
-
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5?Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019. J Pediatr. 2024 08; 271:114045.